## Caigang Xu

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7443795/publications.pdf

Version: 2024-02-01

1684188 1281871 17 131 5 11 citations h-index g-index papers 22 22 22 223 citing authors all docs docs citations times ranked

#	Article	IF	CITATIONS
1	Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations. Lancet Oncology, The, 2020, 21, 306-316.	10.7	49
2	Assessment of the circulating cell-free DNA marker association with diagnosis and prognostic prediction in patients with lymphoma: a single-center experience. Annals of Hematology, 2017, 96, 1343-1351.	1.8	27
3	Circulating exosomal microRNAs as diagnostic and prognostic biomarkers in patients with diffuse large Bâ€cell lymphoma. Hematological Oncology, 2022, 40, 172-180.	1.7	14
4	Evaluation of Automatically Assigned Job-Specific Interview Modules. Annals of Occupational Hygiene, 2016, 60, 885-899.	1.9	10
5	Predicting treatment response of patients with extranodal natural killer/Tâ€cell lymphoma based on levels of <scp>PDâ€L1 mRNA</scp> and soluble <scp>PDâ€L1</scp> . Hematological Oncology, 2020, 38, 467-477.	1.7	9
6	The expression and clinical significance of programmed cell death receptor 1 and its ligand in tumor tissues of patients with extranodal nasal NK/T cell lymphoma. Scientific Reports, 2022, 12, 36.	3.3	7
7	Prognostic significance of p53, Sox11, and Pax5 co-expression in mantle cell lymphoma. Scientific Reports, 2021, 11, 11896.	3.3	4
8	Circulating Exosomal microRNA Signature As a Noninvasive Biomarker for Diagnosis of Diffuse Large B-Cell Lymphoma. Blood, 2018, 132, 5406-5406.	1.4	4
9	Age-related differences of genetic susceptibility to patients with acute lymphoblastic leukemia. Aging, 2021, 13, 12456-12465.	3.1	2
10	Evaluation of different staging systems and prognostic analysis of nasal-type extranodal NK/T-cell lymphoma based on consistent LVDP chemotherapy regimen. Translational Oncology, 2022, 21, 101437.	3.7	2
11	Methods to develop a scoring system for disease severity classification: More than clinical experience and expertise. European Journal of Internal Medicine, 2017, 37, e12.	2.2	O
12	$\hat{I}^{3}\hat{I}^{T}$ Cell Is Impacted to Erythropoiesis Suppression in Patients with Acquired Pure Red Cell Aplastic Anemia Blood, 2004, 104, 3708-3708.	1.4	0
13	Long Term Survival of Patients with Chronic Myelocytic Leukemia after Allogeneic Stem Cell Transplant Using a Reduced Intensity Regimen of Melphanlan, Lomustine and Cyclophosphamide Blood, 2005, 106, 5308-5308.	1.4	O
14	Homoharringtonine and Low-Dose Cytosine Arabinoside Combined with G-CSF or GM-CSF Administered in Patients with Advanced Myelodysplastic Syndromes and Relapsed or Refractory Acute Myeloid Leukemia Blood, 2007, 110, 1465-1465.	1.4	0
15	Prevention Effects of Schisandrin B on Cardiotoxicity Induced by Anthracyclines in Rabbit Model. Blood, 2008, 112, 5030-5030.	1.4	O
16	Researches for the Effects and Mechanisms of Recombinant Human Erythropoietin Administrated in BALB/c Murine Models with Multiple Myeloma Blood, 2009, 114, 4929-4929.	1.4	0
17	Diagnostic Value of protocadherin 15 on NK/T Cell Lymphoma. Blood, 2014, 124, 5396-5396.	1.4	0